MedElevator
Войти в исследования Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mak Josephine, Khan Sana, Britton Amadea, Rose Spencer, Gwynn Lisa, Ellingson Katherine D, Meece Jennifer, Feldstein Leora R, Tyner Harmony, Edwards Laura J, Thiese Matthew S, Naleway Allison, Gaglani Manjusha, Solle Natasha, Burgess Jefferey L, Lamberte Julie Mayo, Shea Meghan, Hunt-Smith Taryn, Caban-Martinez Alberto, Porter Cynthia, Wiegand Ryan, Rai Ramona, Hegmann Kurt T, Hollister James, Fowlkes Ashley, Wesley Meredith, Philips Andrew L, Rivers Patrick, Bloodworth Robin, Newes-Adeyi Gabriella, Olsho Lauren E W, Yoon Sarang K, Saydah Sharon, Lutrick Karen
Аннотация
METHODS: This study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with test-confirmed severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) between 28 June 2021 and 14 September 2022 were surveyed for PCCs, defined by symptoms lasting >4 weeks after initial infection. Cases self-reported PCCs and controls self-reported no PCCs. The exposure was messenger RNA (mRNA) COVID-19 vaccination (2 or 3 monovalent doses). Odds of PCCs among vaccinated and unvaccinated persons were compared with logistic regression.
RESULTS: Of 936 participants, 23.6% reported PCCs and 83.2% were vaccinated. Participants who received 3 vaccine doses had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (adjusted odds ratio [95% confidence interval]: 0.37 [.16-.85], 0.56 [.32-.97], and 0.48 [.25-.91], respectively).
CONCLUSIONS: COVID-19 vaccination protected against development of PCCs among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important PCCs prevention tool.